Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the transcript. The company is focused on organic growth and is exploring suitable business expansion opportunities. The management has not indicated any intentions regarding fresh capital raising. The primary financial discussions revolve around revenue growth, profitability, NSE listing, and operational matters, with no references to debt or equity fundraising activities.

Any current/future capex/capital investment/strategic investment?

The transcript does not explicitly mention any detailed ongoing or planned capital expenditure (capex) or strategic investments. There is a reference to capacity utilization at 17% on an expanded capacity in FY20, indicating potential room for future capex to increase utilization. The company is focused on backward integration in some products, such as manufacturing raw material DCMP for sulfadoxine, which suggests ongoing strategic manufacturing investments. Management highlights efforts toward cost reduction and operating efficiency, implying indirect investments in process improvement rathe

Future growth expectations in sales/revenue/volumes?

The company targets a revenue of Rs. 800 crores in the next five years, aiming for a 15% year-on-year growth. For the financial year 2022, the anticipated total revenue is around Rs. 565 crores, with confidence to achieve this target despite COVID-related demand fluctuations. The top-line for financial year 2023 is expected to reach Rs. 600 crores, reflecting continued growth. Quarterly manufacturing turnover expectations include approximately Rs. 130-140 crores in Q4 and Rs. 190 crores mentioned for some quarters, indicating varying projections. The company plans to launch at least five new p

Future growth expectations in earnings/operating earnings/profits/EPS?

For the financial year 2022 (FY22), Anuh Pharma anticipates: - Total revenue (top line) of approximately Rs. 565 crores, reflecting around 30% growth from Rs. 432 crores in the previous year. - EBITDA margin calibrated to around 10%, revised down from earlier estimates of 12-15% due to product mix changes and cost escalations. - EBITDA expected to be around Rs. 50 crores by March 2022. For the financial year 2023 (FY23): - Top line target set at Rs. 600 crores. - EBITDA target of Rs. 67 crores. Margins are expected to be between 10-12% pessimistically for EBITDA. Net profit targets a

Anuh Pharma LtdQ3 FY22Pharmaceuticals & Biotechnology

Anuh Pharma Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹89.8P/E: 20.5Market Cap: ₹906 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company targets a revenue of Rs. 800 crores in the next five years, aiming for a 15% year-on-year growth.
For the financial year 2022, the anticipated total revenue is around Rs. 565 crores, with confidence to achieve this target despite COVID-related demand fluctuations.
The top-line for financial year 2023 is expected to reach Rs. 600 crores, reflecting continued growth.
Quarterly manufacturing turnover expectations include approximately Rs. 130-140 crores in Q4 and Rs. 190 crores mentioned for some quarters, indicating varying projections.
The company plans to launch at least five new products annually to expand its market share.
Backward integration efforts are ongoing to reduce reliance on imports and improve margins.
The focus is on organic growth and capital expenditure on capacity expansions to support sales volume increases.

Margin guidance

Category 3

For the financial year 2022 (FY22), Anuh Pharma anticipates:
- Total revenue (top line) of approximately Rs. 565 crores, reflecting around 30% growth from Rs. 432 crores in the previous year.
- EBITDA margin calibrated to around 10%, revised down from earlier estimates of 12-15% due to product mix changes and cost escalations.
- EBITDA expected to be around Rs. 50 crores by March 2022.
For the financial year 2023 (FY23):
- Top line target set at Rs. 600 crores.
- EBITDA target of Rs. 67 crores.
Margins are expected to be between 10-12% pessimistically for EBITDA.
Net profit targets are less definitive due to factors like mark-to-market fluctuations.
The company is confident of achieving these targets despite market and COVID-19 demand volatility.

See what Anuh Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity in the transcript.
The company is focused on organic growth and is exploring suitable business expansion opportunities.
The management has not indicated any intentions regarding fresh capital raising.
The primary financial discussions revolve around revenue growth, profitability, NSE listing, and operational matters, with no references to debt or equity fundraising activities.

Order book

The transcript does not explicitly mention specific details about the current or expected order book or pending orders. However, key points related to business outlook and order expectations include: - The company is confident of achieving a manufacturing turnover of approximately ₹190 crores in the last quarter of the financial year. - For the full financial year 2022, Anuh Pharma anticipates a top line of around ₹565 crores, reflecting about 30% growth over the previous year. - The management expects to reach ₹600 crores in revenue in the next financial year (FY 23). - Backward integration and capacity expansions are being pursued to support growth and improve margins. - New product launches at a rate of about five per year are planned to penetrate and increase market share. No explicit quantification of order book or pending orders is provided.

See what Anuh Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The transcript does not explicitly mention any detailed ongoing or planned capital expenditure (capex) or strategic investments.
There is a reference to capacity utilization at 17% on an expanded capacity in FY20, indicating potential room for future capex to increase utilization.
The company is focused on backward integration in some products, such as manufacturing raw material DCMP for sulfadoxine, which suggests ongoing strategic manufacturing investments.
Management highlights efforts toward cost reduction and operating efficiency, implying indirect investments in process improvement rather than explicit large capex.
No specific figures, timelines, or upcoming project announcements related to capital or strategic investments are disclosed in the provided pages.

Track Anuh Pharma Ltd — get its next earnings analysis in your feed

How does Anuh Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAnuh Pharma Ltd

Rev 2Mar 3

See where Anuh Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Anuh Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Anuh Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Anuh Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →